MA
Mark Andrew Wilson
About Mark Andrew Wilson
Data last updated:
Mark Andrew Wilson is a Director at Nektar Therapeutics (India) Private Limited (since 2019). The company operates in Pharma. Nektar Therapeutics (India) Private Limited reported revenue of ₹3.39 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Nektar Therapeutics (India) Private Limited U24239TG2005FTC046253 | Director | 19 Mar 2019 | 2005 | ₹3.39 Cr (FY 2025) | Active |
Board colleagues of Mark Andrew Wilson
| Name | DIN | Company | Designation |
|---|---|---|---|
| Phaneendra Modali | Nektar Therapeutics (India) Private Limited | Company Secretary | |
| Robert Michael Bacci | 10671198 | Nektar Therapeutics (India) Private Limited | Director |
| Uday Chandra Yemmanuru | 01581364 | Nektar Therapeutics (India) Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mark Andrew Wilson
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mark Andrew Wilson
Mark Andrew Wilson currently holds 1 directorship: Nektar Therapeutics (India) Private Limited (Director, since 19 Mar 2019, revenue ₹3.39 Cr (FY 2025)).
Mark Andrew Wilson was first appointed on 19 Mar 2019 as Director at Nektar Therapeutics (India) Private Limited.
The current boards of Mark Andrew Wilson's companies include Phaneendra Modali (Nektar Therapeutics (India) Private Limited), Robert Michael Bacci (Nektar Therapeutics (India) Private Limited), Uday Chandra Yemmanuru (Nektar Therapeutics (India) Private Limited).